Veracuity Blog Digital epidemiology in pharmacovigilance One of the most important shortcomings of the current pharmacovigilance data collection system is the fact that the FDA Adverse Drug Event Reporting System (FAERS) does not provide any insight into the incidence, prevalence, and rates of occurrence of adverse drug events in the post-approval period [1]. To improve…
DetailsVeracuity Blog Pharmacovigilance at a crossroads The global pharmacovigilance market is growing and is still expected to grow. In 2013, post-market safety surveillance accounted for 60% of the global pharmacovigilance market and should reach $6 billion by 2020. Main drivers for increased reporting of adverse drug reactions include compliance requirements and liability resulting from high-profile…
DetailsVeracuity Blog The compliance trap Pharmaceutical industry is a tightly regulated business, especially in the U.S. and in Europe. Before medicines reach the market, they must undergo extensive clinical testing. Upon reaching the market, approved drugs can be prescribed to any patient if the physician can reasonably expect therapeutic benefit for the specific patient. Clinical…
DetailsVeracuity Blog The cost of patient harm U.S. health care spending reached $3.5 trillion in 2017, of which hospital care was $1.1 trillion and physician and clinical services was $694 billion. Retail prescription drugs cost $333.4 billion [1]. The cost of drug-related patient injury, referred to adverse drug events (ADEs) in the U.S. is estimated…
Details